Discussion Principal findings We modelled the effects and costs of widespread use of SGLT2is and GLP-1 RAs in the total and secondary prevention populations with type 2 diabetes in Australia, considering only their benefits on major cardiovascular and kidney outcomes, from 2020 to 2040
Limitations of Current Research Many studies are preclinical Human mechanistic trials remain limited Microbiome responses vary individually Diet, sleep, stress, and medications influence outcomes GLP-1 regulation is multi-factorial The microbiome is one variable within a complex endocrine network
This is done because the body cannot absorb vitamin C by consuming foods containing it
Renata Gomes Wonderful clinic, in all these years in America I have never seen a clinic with super polite people who speak 3 different languages, a super clean and pleasant environment and I loved the reception with snacks and water for customers
Always calculate the final concentration before converting an amount into milliliters or syringe units
Tirzepatide cost varies a lot between research-grade and prescription Mounjaro / Zepbound channels